Stock Ratings / Health Care / KMTS / financials

ATEC (38) XRAY (46) LMAT (74) INSP (61) ⌘ Pro Terminal →

Kestra Medical Technologies Ltd. (KMTS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$30.61 +2.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $30.69

Kestra Medical Technologies Ltd. (KMTS) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $1.82B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $30.69 (+0.26%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KMTS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY KMTS SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (33% of score)

Altman Z-Score 9.65 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$26.98+1% Next Q

Q2 (-2Q)

Grade E$27.24+5.6% Next Q

Q3 (-1Q)

Grade D$28.76+6.4% Next Q

Current

Grade D-$30.61-6.7% Hist 90D α

Trajectory: E (35) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KMTS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KMTS currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($26.69) and Max Pain ($32.14) forces dealer call-delta covering toward $33.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KMTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KMTS Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How KMTS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $27.8M

FY24

Rev $59.8M

FY25

Rev $95.1M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$95.1M	51.4%	-80%	-$131.6M	-$116.6M	-45%
FY 2024	$59.8M	40.5%	-80%	-$113.8M	-$100.5M	-35%
FY 2023	$27.8M	51.4%	-80%	-$94.1M	-$72.2M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KMTS)

✓Walkthrough of KMTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KMTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.73%▲ RESISTANCE BREAKOUT

2026-10-30O $30.73H $31.06L $28.77C $30.61VOL 324.9K

RES: $30.20SUP: $23.27SMA50: $26.69SMA200: $23.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KMTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KMTS Butterfly Map → + Track KMTS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +59.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KMTS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KMTS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KMTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KMTS)

Health Care Rank #541 of 1016 ⚔️ ATEC vs KMTS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KMTS vs. ATEC, XRAY, LMAT, INSP)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kestra Medical Technologies Ltd. (KMTS) ranks #541 by composite RQD confidence (43/100, grade D-) and #278 by equity capitalization ($1.82B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. LMAT currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with KMTS at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KMTS ACTIVE Kestra Medical Technologies Ltd.	D-	43/100	—	51.4%	-35.0%	+2.48%	$1.82B	Benchmark Subject
ATEC Alphatec Holdings Inc.	D-	38/100	—	69.6%	-18.4%	-0.70%	$1.76B	/atec-vs-kmts →
XRAY DENTSPLY SIRONA Inc.	D	46/100	—	50.0%	-11.0%	+1.80%	$1.92B	/xray-vs-kmts →
LMAT LeMaitre Vascular Inc.	B	74/100	33.8x	71.5%	14.7%	+2.90%	$1.95B	/lmat-vs-kmts →
INSP Inspire Medical Systems Inc.	C-	61/100	14.2x	85.4%	6.0%	+0.30%	$2.06B	/insp-vs-kmts →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001877184

In its most recent audited fiscal period (FY2025, filed 2026-04-30), Kestra Medical Technologies Ltd. (KMTS) reported GAAP revenue of $95.1M (+59.0% vs. FY2024 revenue of $59.8M , and +242.0% cumulative change since FY2023) , GAAP net income of -$131.6M, operating cash flow of -$81.7M, and free cash flow of -$116.6M (-16.0% YoY). On the balance sheet, KMTS closed FY2025 with $379.3M in total assets against $42.3M in total debt (Altman Z-Score: 9.65, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-04-30	$95.1M	-$131.6M	-$81.7M	-$116.6M	$379.3M	$42.3M
FY2024 (FY)	2025-04-30	$59.8M	-$113.8M	-$77.6M	-$100.5M	—	—
FY2023 (FY)	2024-04-30	$27.8M	-$94.1M	-$72.2M	-$72.2M	—	—

3. KMTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KMTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Kestra Medical Technologies Ltd. (NASDAQ: KMTS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $30.61 (+2.48% 1D, market cap $1.82B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KMTS ranks #541 in composite RQD confidence.

How does KMTS compare to ATEC and XRAY in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), KMTS carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 51.4%, and ROIC of -35.0%. By comparison, ATEC (Alphatec Holdings Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -18.4%, cap $1.76B) and XRAY (DENTSPLY SIRONA Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -11.0%, cap $1.92B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KMTS?

Per KMTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001877184), Kestra Medical Technologies Ltd. generated $95.1M in revenue (+59.0% YoY), -$131.6M in net income, and -$116.6M in free cash flow against $379.3M in total assets and $42.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KMTS trading relative to its 50-day, 200-day, and 52-week technical levels?

KMTS last traded at $30.61 (+2.48% on volume of 470,684 shares), positioning the stock +14.69% above its 50-day simple moving average ($26.69) and +28.56% above its 200-day simple moving average ($23.81). Across its 52-week range of $17.34 to $31.06, KMTS sits at the 96.7% percentile with a 14-day RSI of 57.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($26.78 to $34.44).

KMTS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Kestra Medical Technologies Ltd. (KMTS)?

In FY 2025 (10-K), KMTS converted $95.1M of revenue into a 51.4% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: KMTS RQD Cockpit KMTS 12M Forecast KMTS Earnings & Move KMTS Dividends & DRIP KMTS Insiders & 13F KMTS Whale Options KMTS Profit Sankey KMTS News & Why